ENTX: Entera Bio Corp Price to Sales

Symbol and logo of brand Entera Bio Ltd. (ENTX)

Strong investor confidence in Entera Bio Ltd. (ENTX) is driven by its breakthrough peptide delivery system. This historical P/S chart illustrates the business valuation trend, with the current metric standing at 1512.30. The company's revenue is based on bringing tablet-form hormones to market. Success in replacing injections with oral forms will provide the firm with exceptional pricing power in negotiations with industry behemoths.

ENTX (Entera Bio Ltd.) Market Cap to Revenue history from 07/04/2022 to 05/09/2026

Metric breakdowns and analytics for Entera Bio Ltd. (ENTX)

- share price and consensus valuation forecast:
Price Performance Chart enterabio.com|ENTX - Analyst Consensus Forecast
- market capitalization information:
Market Value Entera Bio Corp|ENTX - Total Company Value
- shareholders' equity book value data:
Equity per Share Entera Bio|ENTX - Company Net Assets|Market Cap to Book Value Multiple enterabio.com|ENTX - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Entera Bio Ltd.|ENTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital enterabio.com|ENTX - Company Aggregate Debts|Debts to Book Capitalization Entera Bio Corp|ENTX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Entera Bio|Quick Liquidity enterabio.com
- net income and valuation multiples indicators:
ENTX - Net Profit|Company Profit Forecast Entera Bio Ltd.|ENTX - Price to Earnings Ratio|Projected Price to Earnings Ratio enterabio.com|ENTX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Entera Bio Corp|ENTX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Entera Bio|ENTX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months enterabio.com|ENTX - Earnings growth in current year|Projected earnings per share growth rate for next year Entera Bio Ltd.
- sales revenue and business income indicators:
ENTX - Company Sales|Company Future Sales enterabio.com|ENTX - P/S Multiple|Market Cap to Future Revenue Ratio Entera Bio Corp
General company analysis:ENTX Entera Bio Ltd
Mass-produced product of Entera Bio

The P/S multiple determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of sales. Analysis of the price-to-sales ratio reveals actual transaction dynamics, excluding subjective analyst forecasts. This metric is highly sensitive to changes in capitalization, reflecting market expectations for future cash flows. For Entera Bio Ltd. (ENTX) and its R&D potential in oral molecule delivery, this indicator serves as a measure of investor confidence in the commercialization of patents.

Who Entera Bio Ltd. competes with

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|Verona Pharma PLC (VRNA) - Price to Sales|MENS - Price-to-Revenue Ratio|LGND (Ligand Corp) - Market Cap to Revenue Ratio|AMRX (Amneal Pharmaceuticals) - Market Cap to Revenue|PRGO: Market Cap to Sales Volume|ALVO (Alvotech SA) - P/S Multiple|Price to Sales Liquidia Corp LQDA|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP (ANI Pharmaceuticals Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple MNKD (MannKind Corporation)|P/S Multiple amphastar.com AMPH|PCRX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SPRY (ARS Pharmaceuticals Inc)|TBPH: P/S Multiple|AQST (Aquestive Corp) - Price-to-Revenue Ratio|SCPH (scPharmaceuticals, Inc.) - P/S Multiple|Tectonic (TECX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Tonix Pharmaceuticals Holding Corp. (TNXP)|SXTC - Price to Sales|Eupraxia Pharmaceuticals Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio BHST|EXOZ - Price-to-Revenue Ratio|ORMP: Price-to-Revenue Ratio|HYFT (MindWalk Holdings Inc.) - Market Cap to Revenue|ABVC: Market Cap to Sales Volume|CPIX (Cumberland Pharma) - P/S Multiple|Market Cap to Revenue Ratio QNTM (Quantum BioPharma Corp)|Market Cap to Revenue FGEN (FibroGen, Inc.)|Price-to-Revenue Coefficient telomirpharma.com|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|Synergy CHC Corp. (SNYR) - Price to Sales|RLYB - Price-to-Revenue Ratio|LEXX (Lexaria Bioscience) - Market Cap to Revenue Ratio|PULM (Pulmatrix, Inc.) - Market Cap to Revenue|PTHL: Market Cap to Sales Volume|Market Cap to Revenue APM|Market Cap to Revenue Ratio LYRA (Lyra Therapeutics Inc.)|Price-to-Revenue Ratio Impact BioMedical (IBO)|TNFA: Price-to-Sales Ratio|P/S Multiple YCBD (cbdMD)|Market Capitalization-to-Revenue Ratio PRFX|Auris Medical - P/S Multiple|LIPO - P/S Multiple|Optinose (OPTN) - Price-to-Revenue Ratio|Pieris Pharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Procaps Group S.A.|Market Cap to Revenue petrospharma.com (PTPI)|P/S Multiple QLI|P/S Multiple Acelyrin Inc. (SLRN)|TFF Pharma - Market Cap to Revenue